REG - Wellnex Life Limited - Market Update

Wellnex LifeAnnouncement

16/01/2026 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260116:nRSP1414Pa&default-theme=true

RNS Number : 1414P  Wellnex Life Limited  16 January 2026

 

 

 

ASX/AIM
Announcement
16 January 2026

 

Market Update

 

Wellnex Life Limited (ASX/AIM:WNX) ("Wellnex Life" or the "Company")
announces that Executive Chairman, Ash Vesali, is today providing the
following update to shareholders, ahead of the Company's unaudited results for
the 6 months to 31 December 2025.

 

Highlights:

·     H1 FY26 EBITDA improved by $2.4 million versus prior comparative
period ("PCP")

·     Gross margin increased from 22.8% to 31.3%

·     December 2025 EBITDA up $0.7 million year-on-year

·     Group operating at breakeven as at Q2 FY26 close

·     Pain Away quarterly sales (Q2 FY26) at $3.3 million with gross
margin improved by 7.6%

·     New distribution secured: Priceline for new SKUs, three major
wholesaler NPD launches,

 

Dear Shareholder,

 

Wellnex enters H2 FY26 with improved stability and a clear turnaround
trajectory. The Board and management have taken decisive action to simplify
operations and instill cost discipline, with results now translating into
measurable improvement.

 

Financial Performance

H1 FY26 EBITDA improved by $2.4 million versus the corresponding FY25 period,
with Group gross margin increasing from 22.8% to 31.3%. December 2025
sustained the improvement first realised in November 2025, with EBITDA up $0.7
million year-on-year, driven by lower operating costs. The Group closed Q2
FY26 operating at breakeven, providing a solid platform entering H2 FY26.

 

Pain Away

Pain Away maintained market position while improving profitability in a
competitive category, delivering $3.3 million in quarterly sales (Q2 FY26),
with gross margin improving 7.6%. Heat patches grew 25% in Pharmacy versus 2%
for the category In Australia, lifting market share to 18.5%, a 3-point gain
year-on-year. Roll-ons grew 17% versus 0.3% for the topical pain sector, with
our two SKUs ranked #1 and #3 ahead of a third roll-on launch by the Company
planned in April 2026.

 

Distribution momentum continues, with Priceline launching five new SKUs
[across Australia], and each of Wellnex's three major pharmacy wholesalers
have confirmed four NPD launches. Furthermore, Costco Australia and Costco New
Zealand will trial an exclusive heat patch in April 2026.

 

Contract Manufacturing

We are strengthening our planning discipline and are working with partners to
implement a more productive and sustainable operating model focused on
commercial value delivery.

 

As we move into 2026, Wellnex remains on course to deliver consistent
performance with the goal of creating long-term shareholder value.

 

Happy New Year.

 

Ash Vesali

Executive Chairman

 

 

 

This ASX/AIM announcement has been authorised by the Board of Wellnex Life
Limited (ASX/AIM:WNX).

For further information, please contact:

 

Wellnex Life Limited (ASX:WNX)
                Reach Markets

Ash Vesali
 
               T: 1300 805 941

Executive
Chairman
E: IR@reachmarkets.com.au

E: ash.v@wellnexlife.com.au

 

UK Investors

Strand Hanson (Financial & Nominated Advisor)

James Harris / Richard Johnson      Tel: +44 (0) 20 7409 3494

 

Orana Corporate LLP (Joint
Broker)
swykeham@oranacorp.com (mailto:swykeham@oranacorp.com)

Sebastian Wykeham

 

S.P. Angel Corporate Finance LLP (Joint Broker)        Tel: +44 (0)20
3470 0470

David Hignell / Vadim Alexandre

 

The information contained within this announcement is deemed by the Company to
constitute inside information pursuant to article 7 of EU Regulation 596/2014
as it forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 as amended.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFWESIEMSEIF



            Copyright 2019 Regulatory News Service, all rights reserved